Drug intelligence / Profile preview

CNV1061436

Development stage: Preclinical
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

**CNV1061436** is a small molecule sodium channel blocker developed by Convergence Pharmaceuticals for central nervous system (CNS) disorders. It is designed as a once-daily oral therapy to address limitations of existing CNS drugs, such as poor brain penetration or side effects, by selectively targeting sodium channels like Nav1.5. The compound was Phase I-ready as of 2015 but its development appears to have stalled following Biogen's acquisition of Convergence, with current global R&D status listed as pending.[1][4][5][8]

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on CNV1061436.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNV1061436.

Explore the full profile